PUBLISHER: TechNavio | PRODUCT CODE: 1685656
PUBLISHER: TechNavio | PRODUCT CODE: 1685656
The nuclear medicine market is forecasted to grow by USD 13011.9 million during 2024-2029, accelerating at a CAGR of 19.2% during the forecast period. The report on the nuclear medicine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing adoption of SPECT/CT hybrid imaging systems, rising utilization of nuclear medicine for early disease detection, and growing cancer cases and rising investment in oncology market.
Market Scope | |
---|---|
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 16.1% |
CAGR | 19.2% |
Incremental Value | $13011.9 mn |
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's nuclear medicine market is segmented as below:
By Product
By Application
By Geographical Landscape
This study identifies the minimal side effects of radiopharmaceuticals as compared with its potential benefits as one of the prime reasons driving the nuclear medicine market growth during the next few years. Also, growing research activities to widen applications of hybrid imaging and constant discovery and development of new radiopharmaceuticals will lead to sizable demand in the market.
The report on the nuclear medicine market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading nuclear medicine market vendors that include Bayer AG, Bracco Spa, Cardinal Health Inc., Eckert and Ziegler AG, ECZACIBASI MONROL NUCLEAR PRODUCTS CO., GE Healthcare Technologies Inc., IBA Radiopharma Solutions, Jubilant Pharmova Ltd., Koninklijke Philips NV, Lantheus, Mallinckrodt PLC, Medi-Radiopharma, Mirion Technologies Inc., Necsa, Novartis AG, Siemens Healthineers AG, Sirtex Medical Pty Ltd., Telix Pharmaceuticals Ltd., Tema Sinergie SpA, and TTG Imaging Solutions LLC. Also, the nuclear medicine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: